IDXX Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of 24.31% compared to IDEXX Laboratories's net margin of -9.67%. IDEXX Laboratories's return on equity of 57.29% beat Alnylam Pharmaceuticals's return on equity of --.

IDEXX Laboratories has a consensus price target of $497.46, signalling upside risk potential of 1.17%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.56 which suggests that it could grow by 27.64%. Given that Alnylam Pharmaceuticals has higher upside potential than IDEXX Laboratories, analysts believe Alnylam Pharmaceuticals is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.522, which suggesting that the stock is 52.197% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $998.4M, which are larger than Alnylam Pharmaceuticals quarterly revenues of $594.2M. IDEXX Laboratories's net income of $242.7M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, IDEXX Laboratories's price-to-earnings ratio is 45.44x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 10.35x versus 13.75x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of 24.31% compared to IDEXX Laboratories's net margin of -17.31%. IDEXX Laboratories's return on equity of 57.29% beat Amicus Therapeutics's return on equity of -17.7%.

IDEXX Laboratories has a consensus price target of $497.46, signalling upside risk potential of 1.17%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 164.52%. Given that Amicus Therapeutics has higher upside potential than IDEXX Laboratories, analysts believe Amicus Therapeutics is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.522, which suggesting that the stock is 52.197% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $998.4M, which are larger than Amicus Therapeutics quarterly revenues of $125.2M. IDEXX Laboratories's net income of $242.7M is higher than Amicus Therapeutics's net income of -$21.7M. Notably, IDEXX Laboratories's price-to-earnings ratio is 45.44x while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 10.35x versus 3.36x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 24.31% compared to IDEXX Laboratories's net margin of 50.24%. IDEXX Laboratories's return on equity of 57.29% beat Johnson & Johnson's return on equity of 30.18%.

IDEXX Laboratories has a consensus price target of $497.46, signalling upside risk potential of 1.17%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.36%. Given that Johnson & Johnson has higher upside potential than IDEXX Laboratories, analysts believe Johnson & Johnson is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.522, which suggesting that the stock is 52.197% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $998.4M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. IDEXX Laboratories's net income of $242.7M is lower than Johnson & Johnson's net income of $11B. Notably, IDEXX Laboratories's price-to-earnings ratio is 45.44x while Johnson & Johnson's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 10.35x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 24.31% compared to IDEXX Laboratories's net margin of 28.42%. IDEXX Laboratories's return on equity of 57.29% beat Zoetis's return on equity of 51.03%.

IDEXX Laboratories has a consensus price target of $497.46, signalling upside risk potential of 1.17%. On the other hand Zoetis has an analysts' consensus of $194.12 which suggests that it could grow by 21.88%. Given that Zoetis has higher upside potential than IDEXX Laboratories, analysts believe Zoetis is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.522, which suggesting that the stock is 52.197% more volatile than S&P 500. In comparison Zoetis has a beta of 0.942, suggesting its less volatile than the S&P 500 by 5.835%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.17% to investors and pays a quarterly dividend of $0.50 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $998.4M, which are smaller than Zoetis quarterly revenues of $2.2B. IDEXX Laboratories's net income of $242.7M is lower than Zoetis's net income of $631M. Notably, IDEXX Laboratories's price-to-earnings ratio is 45.44x while Zoetis's PE ratio is 28.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 10.35x versus 7.76x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.